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Prisons have long been associated with rapid transmission of infectious diseases. The HIV/AIDS epidemic
in sub-Saharan Africa (SSA) has fuelled the spread of TB and HIV in prisons. The poor living conditions
and ineffective health services in prisons in SSA are a major breeding ground of Mycobacterium tuber-
culosis (Mtb). The spread of TB between prisoners, prison staff and visitors and the emergence of drug-
resistant TB in prisons now poses a threat to control efforts of national TB programmes in SSA. Accurate
data required to develop appropriate interventions to tackle the ominous problem of TB in African
prisons are scanty and unreliable. The health of prisoners is by default a neglected political issue. This
article reviews the available literature on TB and drug-resistant TB in prisons from SSA countries,
discusses the risk factors for acquiring TB and highlights the priorities for further translational research
in prisons. Ethical issues pertaining to research on captive African populations are discussed. Scientiﬁc,
political and funder attention is required urgently to improve prison health services.
 2010 Published by Elsevier Ltd.1. Introduction and background
Tuberculosis (TB) and HIV/AIDS cause high morbidity and
mortality rates in adults in sub-Saharan Africa (SSA). World Health
Organisation (WHO) recommendations for TB control are focussed
on the early diagnosis and supervised treatment of people in the
community. The ex-South African President and Nobel Prize winner,
Nelson Mandela, developed TB whilst a prisoner on Robben Island,
Cape Town. Prisons have long been known to be associated with
rapid transmission of bacterial, viral, fungal and parasitic infectious
diseases of the skin, gut, genitals and respiratory system. Prisons are
recognised as reservoirs for TB transmission, and surveillance data
from Eastern European prisons show that TB causes signiﬁcant
morbidity and mortality in prison inmates and staff.14, University College London
treet, London W1T 4JF, UK.
Elsevier Ltd.
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), doi:10.1016/j.tube.2010.12.0In SSA, the average TB incidence and prevalence rates are 363/
100,000 and 475/100,0005 respectively. The HIV/AIDS epidemic is
fuelling the spread of TB and up to 70% of adults with TB are co-
infectedwithHIV inmany SSA countries.6 TB inprisons encompasses
not onlyTB inprisoners, but TB inprison staffwhoultimately interact
directly with their families and community when they leave work.
Emerging data show that multi-drug resistant TB (MDR-TB) is also
increasingly being identiﬁed in prisoners and prison staff and poses
a threat to National TB Programmes (NTPs).7,8While there have been
many comprehensive reports of TB in prisons from USA and Europe,
there has been a paucity of literature on TB in African prisons.
Accurate data of TB in prisons in SSA countries are not readily avail-
able since surveillance and data reporting mechanisms are poor or
non-existent. This review summarises the available literature on
epidemiology, diagnosis, treatment and control of TB inprisons from
SSA countries highlighting key priority areas for research and asso-
ciated ethical issues. A case ismade for increased research onpriority
issues andattractingpolitical and funderattentionand investment to
address the neglected problem of TB in SSA prisons.ns in sub-Saharan Africa e the need for improved health services,
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A review of all relevant English language publications on TB in
prisons in SSA was performed of PubMed and Google Scholar
databases. The search used the key words ‘tuberculosis (TB)’,
‘prisons’, ‘prisoners’, ‘inmates’, ‘drug resistance’, and ‘Africa’ linked
with the words ‘epidemiology, treatment, TB control, transmission,
management, conditions, ethics, and prevention’. The search
covered the period July 1st, 1990 up to July 1st, 2010. Review arti-
cles for TB in prisons in general with no geographical restrictions
were collected via a PubMed search using the key words ‘tuber-
culosis’ and ‘prisons’. In addition, the US Centres for Disease Control
and Prevention (CDC) and World Health Organisation (WHO)
websites were searched for relevant information. There were
inherent differences in the methods used to conduct the various
studies and they also varied in emphasis, presentation of data and
study variables.3. Published studies on TB in SSA prisons
Data of TB in prisons from SSA countries show high prevalence
rates affecting upto 5% of inmates. Reports from Zambia, Cameroon,
Tanzania, Malawi, Botswana, and Ivory Coast suggest that the TB
prevalence in prisons is several fold higher than that of TB in the
general population (Table 1). A cross-sectional study of TB in thir-
teen Zambian prisons conducted between 2000 and 2001, enrolled
1080 of a total of 6118 prison inmates, of which 245 (22.7%) had
active TB (prevalence ¼ 4005 per 100,000 inmates). Similar results
were obtained from studies of prisons from Douala, Cameroon. A
retrospective cohort study of 501 prison inmates with active TB at
Butimba prison, Mwanza, Tanzania11 conducted between January
1994 and December 1997 showed a high mortality (16.8%) with 84
deaths, and 112 of 501 inmates (25.9%) were HIV positive. Three
hundred and forty three of the 501 inmates (68.4%) were clinically
classiﬁed as malnourished. The majority of inmates (42.1%) were
diagnosed with TB between 1 and 2 years after incarceration.
In 1996 an active case ﬁnding study was performed in Zomba
Central Prison, the largest prison in Malawi. Of 1315 inmates, 915
(70%) were screened for pulmonary TB of which 47 (5142 per
100,000 inmates) had active TB. Of 22 inmates with TB who agreed
to have a HIV test, 16 (73%) were HIV positive. In most inmates the
symptoms of TB had started after the study participant had entered
prison.15 This study led to policy change in Malawi and the Malawi
National Tuberculosis Control Programme was empowered toTable 1
Summary of TB in prison studies from sub-Saharan Africa.
Country Reference Study site(s) and year(s) of study Main ﬁnd
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treatment of TB in prisons in the country.16
The USA Centres for Disease Control (CDC), in collaborationwith
Botswana government authorities, performed an active case
ﬁnding study screening prison inmates and guards for TB at four
prisons in Gaborone during 2002.13 A total of 1027 (88%) of 1173
prison inmates and 263 (91%) of 288 guards were interviewed. Of
a total of 509 (50%) prisoners that reported cough, 371 (73%)
provided sputum samples of which 39 had TB - a point prevalence
of TB of 3797 per 100,000 inmates (3.8%). Prisons guards had
a point prevalence of 2662 cases per 100,000 (n¼ 7/263). Six out of
20 (30%) study participants, who agreed to be HIV tested, were
positive. Several CDC recommendations resulted from this study,
although these measures have been slow to be implemented.
A prospective study of TB in Bouake prison camp, Ivory Coast
from 1990e1992.14 showed the incidence of active TB to be 5803
per 100,000 inmates (n ¼ 108/1861). In the majority of cases TB
disease was associated with other conditions including malnutri-
tion (75%), anaemia (70%) and dermatoses including scabies (64%).
HIV co-infection was observed in 30% (n ¼ 9/30) of the cases and
alcohol and tobacco dependence in 50%. The 6-month treatment
regimen was effective, with 97.6% of those who completed their
treatment, cured.
4. Prisons e reservoirs of TB impacting on the general
community
Prisons are regulated but not closed systems, due to the
numbers of people who enter, leave and re-enter them. Prison
health is a critical part of public health, as health problems within
and outside prisons are interrelated.17 This has major health
implications regarding the epidemiology of TB and other trans-
mittable diseases within the community.18,19 Sub-standard health
services and TB diagnostic and treatment practices in prisons
compound the risk of MDR-/XDR-TB to the entire population.18
Successful TB control, in any country, requires effective TB control
in prisons. Failure to control TB in prisons has the potential to
disrupt community TB control programmes.18
5. Drug resistant TB data from SSA prisons
The 2010WHOMDR-TB and extensively drug-resistant TB (XDR-
TB) report20 estimates that 440,000MDR-TB cases occurred in 2008
(3.6% of the total incidence of TB), of which 150,000 deaths
occurred worldwide. Accurate data on drug-resistant TB from SSAings (TB prevalence, incidence and HIV co-infection)
TB prevalence was 4005 per 100,000 based on a total prison population of
5/1080 recruited patients were positive for TB) and the authors speculate
TB prevalence rates may approach 15e20%. Resistance to at least one
rculosis drug was detected for 40 (23.8%) isolates, while MDR-TB was identiﬁed
.5%) isolates (MDR-TB prevalence of 262 per 100,000).
prevalence of 3516 per 100,000 (n ¼ 87/2474) with 6/24 (25%) of patients tested
ed with HIV.
B patients, 40.7% were smear positive, 25% were co-infected with HIV and the
of inmates were diagnosed with TB between 1 and 2 years after incarceration
prevalence of smear-positive pulmonary TB was 705 per 100,000 (n ¼ 54/7661)
lence was higher in large urban prisons (1080 per 100,000).
revalence of TB of 3797 cases per 100,000 population (n ¼ 39/1024) in
mates and 2662 cases per 100,000 (n ¼ 7/263) in prison guards with
0) of patients tested co-infected with HIV
sitive TB incidence of 5803 per 100,000 inmates (n ¼ 108/1861)
co-infection observed in 30% (n ¼ 9/30) of cases.
lence of 5142 per 100,000 inmates (n ¼ 47/914) with 73% of those tested
ed with HIV (n ¼ 46/62).
ons in sub-Saharan Africa e the need for improved health services,
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data that show <3% of new TB cases as MDR-TB.7,20 The WHO
estimated that 69,000 cases of MDR-TB emerged in 2008 in Africa,
which is likely to be an underestimate due to lack of any signiﬁcant
laboratory infrastructure required to perform drug susceptibility
testing on a routine basis. In a study based on data from 39 of the 46
countries in Africa, it was estimated that MDR-TB is likely to be
more prevalent than previously recognised.21 Recent surveys from
Ethiopia (retreatment cases)22, Nigeria (tertiary hospital)23, Zambia
(prison)9 and Rwanda (retreatment cases)24 report MDR-TB prev-
alence rates of 26%, 54%, 9.5% and 9.4%, respectively. These data
indicate that MDR-TB prevalence rates are higher than reported by
the WHO.7
Prisons can be an important source of spread for drug-resistant
TB.19 The WHO status report on TB in prisons released in 2007
states that there is an urgent need to ensure effective and efﬁcient
diagnosis and treatment of drug-resistant forms of TB in prisons.25
Many SSA countries simply do not have the resources or organised
health systems for screening, diagnosis and treatment of prison
inmates for TB. For those that are tested for TB, routine drug-
susceptibility testing is not performed. This illustrates the large gap
between what is recommended by the WHO and the real situation
on the ground in SSA prisons. Barriers to implementation of TB
control in prisons include: inadequate TB and TB/HIV health
services and medical staff for prisons; lack of laboratory support;
inadequate infection control measures and lack of resources to
implement them; inadequate discharge planning, contact tracing
and followup after discharge; lack of proper data collection and
surveillance procedures; low priority for national governments
resulting in poor resource allocation.
6. Risk factors for transmission and development of active TB
within prisons
Table 2 lists the factors that promote transmission and devel-
opment of active TB in prisons. In SSA prisons the most important
risk factors are HIV, poor ventilation, overcrowding and malnutri-
tion. Prisons provide ideal conditions for the rapid and effective
transmission of respiratory tract, skin, gastrointestinal and sexually
transmitted diseases.26 According to the WHO, TB propagates in
prisons because of several reasons: prisons receive TB through
prisoners and staff with active TB; prisons concentrate TB; prisons
disseminate TB; prisons make TB worse; and prisons export TB.25 It
is well established that TB is a disease associated withmalnutrition,
stress, immunosuppression, overcrowding, poor housing and
ventilation, factors which are prevalent in prisons. TB thrived in the
UK a hundred years ago, in Victorian times, when these conditions
prevailed.
A recent article in the Lancet titled ‘Death and disease in Zim-
babwe’s prisons’ describes the appalling conditions faced byTable 2
Risk factors for transmission and development of active TB within prisons.
Environmental risk factors Host risk factors
Poor ventilation in prison cells and
congregate settings within the prisons
Poor nutrition and
micronutrient deﬁciencies
Close contact between prisoners due
to restricted prison compounds
Stress and anxiety





(many prisoners per cell)
Smoking, Alcohol, and Chronic
obstructive airways disease
Close contact between prisoners and visitors Addictive drugs
Poor prison health services Lack of sunshine and
vitamin D deﬁciency
Please cite this article in press as: O’Grady J, et al., Tuberculosis in priso
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the healthy slept side by side, coughing at each other and how the
dead and the living often competed for space. An assessment of
Zambia’s prisons, regarding TB and HIV, published by Human
Rights Watch in April this year28 revealed similar ﬁndings. In
October 2009, the Zambia Prisons Service employed only 14 health
staff, including only one physician, to serve its 15,300 prisoners and
only 15 of 86 prisons had a health clinic or sick bay.28,29
7. Achieving TB control in prisons
The prevalence of TB in prisons ultimately reﬂects the efﬁciency
and quality of the country’s NTP. TheWHO has viewed TB in prisons
as an important control issue and published guidelines on TB for
national government TB programmes a decade ago.19 These are
similar to Mtb infection prevention and control measures recom-
mended by the CDC and include: early identiﬁcation of inmateswith
latent TB infection (LTBI) and active TB; prompt isolation of conta-
gious inmates; appropriate use of infection control methods; swift
performance of contact investigations; and successful completion of
treatment for latent and active TB.30,31
In Malawi, the National TB Programme (NTP) and the Prison
Medical Services have effectively worked together to improve the
diagnosis and treatment of TB in prison inmates since 1996.16
Prison inmates are screened for TB on admission and at intervals
during their incarceration. Inmates are treated for TB according to
NTP guidelines. A study, performed in 2005, of 18 prisons inMalawi
showed a prevalence rate of smear-positive TB of 0.7%, which, while
high compared with that of the general population, is lower than
prevalence rates from other prison surveys in Africa, indicating
some measure of programme success.12
8. Overcoming risk factors for TB in prisons
8.1. Living conditions including overcrowding and ventilation
Living conditions in prisons throughout the world are poor. SSA
prisons are among the most overcrowded in the world.28 The
Human Rights Watch report’s recommendations to address TB in
prisons include “improving immediately the ventilation, sunlight,
and cleaning of TB isolation cells in line with international stan-
dards”.28 All SSA country governments are faced with competing
investment needs and prisoner healthcare drops down the list of
priorities.
8.2. HIV screening and treatment
Due to the high prevalence of TB and HIV/AIDS in the local
community, and amongst prisoners in SSA, parallel screening for TB
and HIV is necessary and should be performed regularly in all
prisoners. HIV positive inmates and staff should be provided with
counselling, testing, appropriate treatment and, if necessary,
parallel management of TB and HIV.
8.3. Nutritional status, immunity and TB
Malnutrition and associated poor immunity is associated with
an increased risk of reactivation of latent to active TB and increased
risk of re-infection because of the negative impact of micro and
macronutrient deﬁciencies on the cell-mediated immune system.32
Several studies in various populations have associated vitamin D
deﬁciency with increased risk of TB.3338 Lack of funding, massive
overcrowding and mismanagement of meagre resources are
primary drivers of malnutrition, increased risk of disease and death
in most SSA prisons.27ns in sub-Saharan Africa e the need for improved health services,
02
J. O’Grady et al. / Tuberculosis xxx (2011) 1e648.4. Improving health services
Prison health services are insufﬁcient, in all SSA countries, due
to competing priorities for limited health care funds.25,39 Access to
adequate health care for inmates is therefore limited because of
lack of resources, accommodation, equipment, transport, staff and
infrastructure and consumables such as diagnostic materials and
medicines.19 Prisons have no isolation facilities to treat MDR-/XDR-
TB. These facilities are also absent in teaching hospitals in SSA.
Many MDR-/XDR-TB patients are untreatable, which poses the
question: where should we house prison inmates with MDR-/XDR-
TB and what will happen to them?
8.5. Screening and diagnosis of TB
TB diagnostic methods, if available at prison point-of-care
health services, are often poorly applied.19 Screening of prison
inmates on entry into prison should be made a priority and will
play an important role in early case detection and control of TB.40,41
An inexpensive, accurate, rapid point-of-care TB screening method
is urgently required for active case ﬁnding if the problem of TB in
prisons is to be effectively controlled. A promising new diagnostics
system developed recently is the Xpert MTB/RIF Assay which is
a fully automated closed system that performs both sputum sample
preparation and real-time PCR, producing results in less than 2 h.
The Xpert MTB/RIF Assay, is capable of detecting the Mtb complex
while simultaneously detecting rifampicin resistance. Analytical
sensitivity and speciﬁcity is 100% according to a recent study using
rifampicin resistant and sensitiveMtb isolates and non-tuberculosis
bacteria, fungi and viruses.42 In a recent multi centre evaluation
study published in the New England Journal of Medicine the Xpert
MTB/RIF Assay was 98.2% and 72.5% sensitive on smear-positive
and smear-negative TB patients respectively and was 99.2%
speciﬁc.43 There is a need for this assay to be evaluated and tested
at prisons in Africa and, if appropriate, to be installed for use at
point-of-care in prison clinics. However, the high costs associated
with newer diagnostics technologies such as the Xpert MTB/RIF
Assay will prevent their widespread introduction by SSA countries’
NTPs. However, an important issue is that while rifampicin resis-
tance is relatively easily identiﬁed, due to the fact that resistance is
limited to a few point mutations within the rpoB gene, resistance
testing of other TB drugs is much less straightforward. Until
rifampicin or rifampicin with non-INH drug combinations are
universally recommended for the treatment of latent TB, drug-
susceptibility testing will still rely on the slower culture-based
methods. Rapid methods for detection of resistance to INH and
second line TB drugs are currently being developed.
8.6. Infection control, isolation and treatment
The standard recommendations for infection control, isolation of
patients and protection of medical staff apply to all institutions.
However, these are not implemented in most SSA countries prisons.
This becomes a major issue when prisoners have to be taken to
a central health facility by prison guards for medical assessment.
Thosewith drug-resistant TBpose amajor threat to those involved in
looking after them. The WHO directly observed treatment short
course (DOTS) treatment strategy is well known and, in theory,
should be relatively easy to implement in the captive population of
the prison environment. Paradoxically, however, the prevalence of
drug-resistant TB is often higher in prison populations than in the
civilian population. Those with drug-resistant TB should be treated
according to the latest WHO guidelines.44 Future successes in TB
control will also depend on the development of new anti-tubercu-
losis drugs used in treatment regimens that are shorter to enablePlease cite this article in press as: O’Grady J, et al., Tuberculosis in pris
surveillance and control, Tuberculosis (2011), doi:10.1016/j.tube.2010.12.prison inmate compliance45. Several new TB drugs are currently in
the clinical development which could be effective against MDR-TB,
including the diarylquinolone, TMC-207, which targets mycobacte-
rial ATP synthase46, and Nitroimidazoles, such as PA-824 and OPC-
67683, which are equally active against drug susceptible and drug-
resistant TB and are also being evaluated in clinical trials45. As they
are active against both replicating and non-replicating organisms,
they could potentially shorten treatment of active disease and
provide activity against latent TB infection. Evaluation of the use of
moxiﬂoxacin and TMC-207 in treatment regimens to shorten the
duration of chemotherapy are also ongoing.45
8.7. Isoniazid preventative therapy (IPT) for those with latent
TB or HIV
In an ideal world, all prison inmates should be screened for both
latent and active TB.Whilst IPT is recommended for thosewith latent
TB infection47 thecontroversies surrounding theuseof a singledrugto
which the tubercle bacillusmay be resistant to, and the absence of an
accurate test that can distinguish between latent and active TB,
especially in high TB and HIV endemic areas, it is advisable not to use
singledrugprophylaxisor treatment forprisonerssuspectedofhaving
latent TB infection. Thewhole issue of IPTandMtb latency is currently
being debated and single drug treatment should be avoided.48
8.8. Information and education
Education and training are integral parts of TB and HIV control
programmes in prisons, according to the WHO,19 the aim of which
are to increase awareness and knowledge. Such training should
have a positive impact on attitudes and behaviour of individuals
likely to be affected by TB such as inmates, family, prison personnel
and visitors. Less than 60% of countries surveyed in Europe
provided appropriate health education for TB control in prisons17
and no countries in SSA provide this type of education.
9. Priorities and ethical considerations for research on TB
in prison
Table 3 lists some of the priority unanswered questions
regarding TB in prisons in SSA. The scientiﬁc community need to
focusmore attention on the neglected issue of TB in prisons and the
size of the problem needs urgent deﬁnition for both drug-sensitive
and drug-resistant TB. Priorities for researchmust be identiﬁed and
developed in consultation with local politicians and international
donors. This will provide an evidence base which can help SSA
governments allocate appropriate and adequate funding for
improving prison health care services.
Performing research studies on prisoners (who, by the nature of
their incarceration, are disadvantaged populations that lose many
of their human rights) raises many ethical issues49,50 and lessons
from unethical studies, such as those highly quoted from the USA,
need to be learnt.51,52 SSA countries should develop their own
ethical criteria for research into prisoners and local ethics
committees should be educated on protection of ‘vulnerable indi-
viduals’ and the special role for ethical review committees.53,54
Other ethical questions arise: a) Should improved surveillance be
classed as research when it is already international policy as stated
by the WHO? b) Should implementation of ’proven’ TB control
measures be delayed while operational research is undertaken? c)
Would research on the dynamics of TB transmission be ethical if
infection control measures were not already in place? Prison
inmates, belonging to undervalued social groups such as immi-
grants, social minorities and refugees, can easily be deprived of
their legal rights.4 A careful ethical review should take these pointsons in sub-Saharan Africa e the need for improved health services,
002
Table 3
Unanswered questions regarding TB in SSA prisons.
What is the actual size of the TB and TB/HIV problem
(both drug-sensitive and drug-resistant)
in African country prisons?
- Need to establish quality data recording and reporting system
- Need better quality TB diagnostic, treatment and followup services
- Need point of care rapid diagnostic tests for same day identiﬁcation of active TB cases
- Need point of care raid screening for drug-resistant TB
What resources are required to aim
towards control of TB in prisons?
- Cost of establishing proper health services for prisoners and staff
- Cost of improving/redesigning prison buildings and ventilation of cells
- Cost of better prison food and prison living conditions
- Cost of drug treatment for HIV and drug-resistant TB
- Cost of prison staff developing active TB
What are the priorities that need focussing
upon to improve TB control in prisons?
- Improve and integrate TB/HIV/STD/other health services for prisoners and prison staff
- Deﬁne the magnitude of TB and TB/HIV in prison staff and prisoners
- Deﬁne the problem of drug-resistant TB in prisons
- Improve prison conditions (cell size, ventilation, food)
- Reduce overcrowding of prisons
- Focus governmental and funder attention on problem of TB in prisons
- Deﬁne optimal and cost-effective ways to diagnose TB in prisons
- Deﬁne the optimal screening method for prisoners and staff
What are the transmission dynamics of
Mtb in the prison environment?
- Deﬁne how many new prisoners have active TB on entry to prison
- Deﬁne prevalence rates of active TB in existing prisoners and prison staff
- Deﬁne the prevalence of MDR-/XDR-TB in prisoners and prison staff
- How long it takes before an HIV-infected or uninfected prisoner develops active TB?
- Deﬁne TB transmission to the community by prisoners released after serving their sentence
- Ascertain treatment completion and followup rates of prisoners with active TB released from prison
J. O’Grady et al. / Tuberculosis xxx (2011) 1e6 5into consideration and African country governments must allow
ethical research to be conducted in prison settings to obtain
information for introducing appropriate healthcare interventions.
Furthermore, under research conditions, inmates will receive the
beneﬁt of supervised healthcare management. It is the responsi-
bility of the state and society to ensure that the human right to
health is properly addressed.10. Political support and appropriate ﬁnancing essential
for TB control
It is apparent that TB control will not be achieved until action is
taken by governments at all fronts of the TB problem55. TB, within
conﬁned institutions like prisons, needs to be included in all
planning and investment for TB control. Article 6 of the Interna-
tional Covenant on Civil and Political Rights treaty of the United
Nations General Assembly states clearly that “Every human being
has the inherent right to life. This right shall be protected by law.
No-one shall be arbitrarily deprived of it.” Thus governments have
a moral duty to protect prisoners from harm by disease. Joint
political, scientiﬁc and NTP commitment is required if the TB
epidemic in prisons is to be effectively combated.11. Conclusions
TB in prisons is a neglected area in SSA countries and an
increasing prevalence of active TB is being seen in prisons in SSA.
Apart from HIV, several other preventable factors are driving the
spread of TB within prisons. Drug-resistant TB is increasingly being
detected in SSA prisons and basic epidemiological data on MDR-/
XDR-TB is urgently required. There is a growing concern in the
international community and human rights groups that prisoners
do not have access to good quality medical care and living condi-
tions. All SSA governments need to focus NTPs into improving
prison health services and establishing improved data collection
and surveillance methods. The problem of TB in prisons needs to be
deﬁned through properly designed, ethically conducted research
studies. Only when reliable data is available, can a case for speciﬁc
investments from donor governments and international funding
agencies be made, to bring TB in prisons under control.Please cite this article in press as: O’Grady J, et al., Tuberculosis in priso
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